Reconstructive Surgery for Bladder Exstrophy

Treatment for Urogenital Congenital Anomalies

Effectiveness
90%
Safety Score
50%
Clinical Trials
2
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate anatomical correction, functional continence achieved over years with multi-stage surgeries
Treatment Duration
Multiple surgeries over childhood (birth to adolescence), lifelong follow-up
Evidence Quality
MODERATE
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$5,000
Side Effect Mgmt:$10,000
Total Annual:$100,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
6
Outcome-Based Costs
Cost per Responder
$142,857
Comparison vs Palliative Care / No Definitive Reconstruction
Cost Difference
$0/year
Same cost
QALY Difference
+6.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Reconstructive Surgery for Bladder Exstrophy Outcomes

for Urogenital Congenital Anomalies

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+70%
Common Side Effects
Bladder prolapse
+10%
Bladder neck incontinence
+30%
Urinary tract infection
+35%
Urethral stricture/fistula
+15%
Renal deterioration
+15%
Reoperation for complications
+60%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov